Evolv Technologies (NASDAQ: EVLV) just closed its first profitable year on an adjusted EBITDA basis, grew revenue 40%, and raised 2026 guidance. The stock sits at $6.65 with four analysts pegging the target at $9.12-$10.00. That’s 37-50% upside from here. The question isn’t whether the business is working — it clearly is. The question is whether the market will pay attention before Q1 earnings hit on May 12.
What Evolv Actually Does
Evolv makes AI-powered weapons screening systems. You walk through a sensor portal — no stopping, no emptying pockets, no wanding. The system uses sensor fusion and AI trained on millions of scans to detect threats while ignoring phones, keys, and water bottles. It’s deployed at 1,200+ venues: schools, stadiums, hospitals, theme parks, and corporate offices.
This is the “replace the metal detector” thesis. Metal detectors are slow, labor-intensive, and produce massive lines. Evolv’s Express system screens 60 people per minute. Disney, the NFL, and six of the top 10 US theme parks use it. The addressable market is essentially every building that currently runs a metal detector or wants screening but can’t justify the throughput hit.
FY2025 Results: The Inflection Year
Revenue hit $145.9M, up 40% from $103.9M in FY2024. Q4 alone delivered $38.5M (+32% YoY). Annual recurring revenue (ARR) reached $120.5M, up 21%. The company posted its first full-year positive adjusted EBITDA at $11.1M — a $32M swing from the -$21.0M in FY2024.
Q4 net income came in at $10.9M (28% net margin), though that includes some one-time benefits. The adjusted loss for the full year was -$16.8M, or -$0.10 per share, narrowed from -$35.3M the year before. Operating cash flow flipped from -$30.9M to +$18.7M. That’s the most important number on the income statement: the business is now self-funding.
Cash and marketable securities stood at $69.0M at year-end, up $12.8M sequentially. Total debt is $42.2M. Net cash of $26.8M on a $1.19B market cap — balance sheet is clean.
2026 Guidance: Raised to $178M
Initial guidance called for $172-178M in revenue. The company has already raised the ceiling, with Seeking Alpha reporting the updated target at $178M. ARR is guided to $145-150M by year-end 2026, reflecting 20-25% growth. Half of new deployments in 2026 will use the pure subscription model, which pushes recurring revenue mix higher and smooths out the lumpy hardware revenue.
Here’s why that matters: recurring revenue (subscriptions, software, maintenance) was 77% of total revenue in FY2025 at $112.1M, up 28%. Non-recurring (hardware sales) was $33.8M, up 106% but more volatile. The subscription shift makes revenue more predictable and expands margins over time — the same inflection we saw in Marex Group (MRX) at 11x earnings.
Q1 2026 earnings drop on May 12 after the close. That’s two weeks away. If the company shows continued ARR acceleration and narrows the GAAP loss, expect the stock to move.
The Bull Case
AI security screening is still early. Metal detectors have been the default for 50 years. Evolv has 1,200 customers. There are over 100,000 K-12 schools in the US alone, plus tens of thousands of stadiums, arenas, hospitals, and corporate campuses. Penetration is under 2%.
Operating leverage is kicking in. The $32M EBITDA swing in one year came on 40% revenue growth. As the subscription base compounds, incremental revenue drops more to the bottom line. The 2026 EBITDA margin target is high single digits — achievable if revenue hits $178M.
Operating cash flow is positive. +$18.7M in FY2025 means the company doesn’t need to dilute shareholders to fund growth. Share count grew 7.6% YoY to 179.4M shares, but most of that was from prior SPAC structure, not new issuance.
Analyst consensus is $9.12-$10.00. Four analysts, all Buy ratings. The stock at $6.65 implies the market either doesn’t believe the growth is sustainable or is applying a steep discount for the company’s SPAC origins and past volatility.
The Bear Case
GAAP profitability is still negative. Net loss of -$33.1M in FY2025. The company may not hit GAAP profitability until late 2026 or 2027. At 8.2x price-to-sales, you’re paying a growth premium for a company still burning cash on a reported basis — more expensive than Remitly (RELY) at its profitability inflection, but with a smaller addressable market.
Regulatory and reputational risk. Evolv’s screening has faced scrutiny over false negatives and false positives. A high-profile security failure at a venue using Evolv would be catastrophic for the brand. The company has also dealt with SEC inquiries related to previous management’s disclosures — a pattern we’ve flagged in our small-cap promotion trap checklist.
Customer concentration. Six of the top 10 theme parks are great for a press release, but losing a major contract would materially impact revenue. The company doesn’t disclose customer concentration details, which itself is a yellow flag.
Valuation isn’t cheap. 8.2x sales for a company with -$0.20 EPS. Price-to-book is 9.7x. If growth decelerates below 20%, the stock could contract sharply. The 1.78 beta means it moves harder than the market in both directions.
Share dilution history. The company went public via SPAC and shares outstanding have grown significantly. Another 7.6% dilution in one year. Management needs to prove they can grow without printing shares.
Key Numbers at a Glance
- Market Cap: $1.19B
- FY2025 Revenue: $145.9M (+40% YoY)
- Q4 2025 Revenue: $38.5M (+32% YoY)
- ARR: $120.5M (+21% YoY)
- Adjusted EBITDA: $11.1M (first positive year)
- Net Loss: -$33.1M (-$0.20/share)
- Operating Cash Flow: +$18.7M
- Cash: $69.0M | Debt: $42.2M
- 2026 Revenue Guide: $178M (+22%)
- 2026 ARR Guide: $145-150M (+20-25%)
- Analyst Target: $9.12-$10.00 (Buy consensus)
- Short Interest: 7.38M shares (4.1% of outstanding)
- Next Earnings: May 12, 2026 (after close)
The Trade
EVLV is a classic inflection story. The business just crossed the line from “burning cash to grow” to “self-funding with accelerating margins.” Revenue is growing 40%. ARR compounds. Operating cash flow is positive. And the stock trades 37% below the lowest analyst target.
The catch: this has been a volatile name with a SPAC hangover, and the market has been slow to re-rate it. The 52-week range shows how wild the swings get — the stock is up 70% over the past year but still well below its 200-day moving average of $6.76.
Verdict: Compelling below $6.50. Fair value $7.50-8.50 based on 6-7x forward sales. Expensive above $9 unless Q1 earnings blow out and management raises guidance again. The May 12 earnings call is the near-term catalyst — if ARR growth accelerates and the GAAP loss narrows meaningfully, this stock moves to $8+ quickly. If Q1 disappoints, $5.50 is realistic support.
This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions. The author holds a paper position in EVLV as part of the marginofalpha.com paper portfolio.